Sarepta Therapeutics

Arrowhead Pharmaceuticals, Inc. is a biotechnology company based in Pasadena, California, focused on developing innovative medicines for the treatment of intractable diseases, particularly those with a genetic origin characterized by the overproduction of specific proteins. The company's diverse pipeline includes RNA interference (RNAi) therapeutics such as ARO-AAT for liver diseases associated with alpha-1 antitrypsin deficiency, ARO-APOC3 for hypertriglyceridemia, and ARO-HIF2 for clear cell renal cell carcinoma, among others. Arrowhead is also exploring treatments for various conditions, including chronic hepatitis B virus infection and cardiovascular diseases. The company collaborates with prominent pharmaceutical firms, including Janssen Pharmaceuticals and Takeda Pharmaceuticals, to develop additional RNAi therapeutic candidates. Originally founded as Arrowhead Research Corporation in 1989, it adopted its current name in April 2016.

Lexeo Therapeutics is a biotechnology company specializing in adeno-associated virus (AAV)-mediated therapies for both rare and common diseases caused by single gene mutations. Headquartered in New York, the company maintains an integrated pipeline developed in collaboration with Weill Cornell Medicine's Department of Genetic Medicine. Lexeo focuses on advancing its clinical programs towards commercialization while continuing to research new therapies for various patient populations and unmet medical needs.

StrideBio, Inc. is a gene therapy company based in Durham, North Carolina, focused on developing innovative genetic medicines for rare diseases. Founded in 2015, the company utilizes a proprietary structure-inspired adeno-associated virus (AAV) vector engineering platform to create unique and differentiated vectors. These vectors are designed to improve upon naturally occurring AAV serotypes, addressing limitations of first-generation gene therapies. StrideBio's technologies facilitate gene addition, silencing, and editing, providing potential curative options for patients with severe medical conditions. By combining structural insights with accelerated evolution, StrideBio aims to produce novel AAV capsids capable of evading neutralizing antibodies, ultimately enhancing treatment outcomes for those affected by rare diseases.

AavantiBio, Inc. is a biopharmaceutical company focused on developing gene transfer and gene editing therapies aimed at treating rare genetic diseases. Incorporated in 2019 and based in Gainesville, Florida, the company primarily concentrates on Friedreich’s Ataxia, a rare inherited disorder that leads to significant cardiac and central nervous system dysfunction. AavantiBio is committed to transforming the lives of patients suffering from this condition by advancing innovative therapies that address unmet medical needs in the field of genetic disorders. The company’s efforts are directed toward both treatment development and research, with the goal of providing effective solutions for patients facing the challenges of rare diseases.

Myonexus Therapeutics is a clinical stage company focused on developing gene therapies for rare diseases, specifically targeting Limb-girdle muscular dystrophy (LGMD) Types 2D, 2B, 2E, 2L, and 2C. The company is rooted in research conducted at Nationwide Children’s Hospital, which is recognized for its expertise in muscular dystrophy gene therapy and translational research. Myonexus aims to pioneer the first effective treatments for these specific LGMD types, utilizing advanced precision genetic medicine approaches. In addition to LGMD, the company’s innovative therapies show potential for addressing other genetic disorders, including Charcot-Marie-Tooth disease, MPS IIIA, and Pompe disease, among others.

Lacerta Therapeutics, Inc. is a clinical-stage gene therapy company based in Alachua, Florida, focused on developing innovative treatments for central nervous system and lysosomal storage diseases. Established in 2017, the company leverages a unique array of proprietary adeno-associated virus (AAV) vector technologies to advance its therapeutic programs. Lacerta Therapeutics is distinguished by its expertise in the development, production, and application of AAV vectors, utilizing proprietary capsid variants and a scalable vector manufacturing platform. The founders and team possess extensive experience in AAV gene therapy, contributing to the company's capabilities in basic vector development and clinical trial execution. Through these advancements, Lacerta Therapeutics aims to provide effective treatment options for patients suffering from neurological and lysosomal storage disorders.

Myonexus Therapeutics is a clinical stage company focused on developing gene therapies for rare diseases, specifically targeting Limb-girdle muscular dystrophy (LGMD) Types 2D, 2B, 2E, 2L, and 2C. The company is rooted in research conducted at Nationwide Children’s Hospital, which is recognized for its expertise in muscular dystrophy gene therapy and translational research. Myonexus aims to pioneer the first effective treatments for these specific LGMD types, utilizing advanced precision genetic medicine approaches. In addition to LGMD, the company’s innovative therapies show potential for addressing other genetic disorders, including Charcot-Marie-Tooth disease, MPS IIIA, and Pompe disease, among others.

Eisai, established in 1941, is a global human healthcare company headquartered in Japan. It operates as an integrated pharmaceutical business, focusing on two core therapeutic areas: oncology and neurology, including dementia-related and neurodegenerative diseases. Eisai's business spans multiple regions, with significant operations in Japan, the Americas, China, Asia, and Europe, Middle East, and Africa. The company's portfolio comprises prescription medicines for various indications, including central nervous system disorders, metastatic breast cancer, and diabetes. Eisai India, a 100% subsidiary, was the first Japanese company to enter the Indian pharmaceutical market, offering a range of products and maintaining a dedicated field force. Eisai's manufacturing and research complex in Vizag, India, produces drug substances, drug products, and conducts developmental research, with certifications from regulatory bodies such as USFDA, PMDA, MHRA, and WHO. Eisai Inc., its U.S. subsidiary, is committed to addressing unmet healthcare needs and fostering strong alliances. Eisai Innovation, a strategic investment organization, seeks synergies between the scientific community and Eisai's network.

Ercole Biotech, Inc. is a research-stage biopharmaceutical company based in Research Triangle Park, North Carolina. Founded in 2002, the company specializes in the development of oligonucleotide drugs that achieve therapeutic effects by directing the alternative splicing of target genes. Ercole Biotech focuses on manufacturing these innovative medicines to treat various diseases through the modulation of target genes. As of March 2008, it operates as a subsidiary of AVI Biopharma, Inc.